National Bank of Canada
JANX icon

National Bank of Canada’s Janux Therapeutics JANX Stock Holding History

National Bank of Canada’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.84K Buy
+277
New +$3.8K ﹤0.01% 2513
2024
Q4 		– Sell
-1
Closed -$45 – 3069
2024
Q3 		$45 Buy
+1
New +$44 ﹤0.01% 2596

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

National Bank of Canada's JANX Position: Q1 2026 in Review

National Bank of Canada opened a new position in Janux Therapeutics (JANX) in Q1 2026: 277 shares worth $3.84K. The stake represents ﹤0.01% of the portfolio and ranks #2513 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in JANX as recently as Q3 2024.

National Bank of Canada first reported a position in JANX in Q3 2024 and has held it in 2 quarters since. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • National Bank of Canada held 277 shares of Janux Therapeutics worth $3.84K as of Q1 2026.
  • Janux Therapeutics was a new National Bank of Canada position in Q1 2026.
  • Janux Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2513 holding.
  • National Bank of Canada first reported a position in Janux Therapeutics in Q3 2024 and has held it in 2 quarters since.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.